A trade group representing compounding pharmacies has filed a lawsuit against the Food and Drug Administration (FDA) for ...
On February 21, 2025, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order determining that the semaglutide ...
Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s ...
Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...
If Australia followed England’s lead and listed drugs such as Wegovy on the PBS for weight loss, this could bring the cost ...
A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another ...
There used to be no specific treatments for heart failure with preserved ejection fraction, but recent clinical trials show ...
With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared ...
Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...
Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.
Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” ...
Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular ...